# A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1

Source: https://onco.cc/trials/nct07024784/  
OnCo record `nct07024784` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carboplatin, Bevacizumab, Olaparib in ovarian cancer, run by AbbVie, now recruiting.

## Summary

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies is a phase 2 interventional study registered as NCT07024784 by AbbVie, with 377 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-01. Interventions recorded: IMGN151, Carboplatin, Bevacizumab, Olaparib. Conditions listed: Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07024784
- Phase: 2
- Setting: A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers
- Sponsor: AbbVie
- Enrolled: 377

## Sources

- ClinicalTrials.gov NCT07024784: https://clinicaltrials.gov/study/NCT07024784

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct07024784.json